Maximizing ADA immunoassay drug tolerance and sensitivity using an automated, microfluidic approach

• ADA assays need to be robust and sensitive for evaluation of the immunogenic potential of biologic immunotherapies
• Automating acid dissociation in a microfluidic format using Gyrolab® platform provides rapid, drug tolerant automated immunoassays
• Data demonstrating Keytruda® and Actemra® Gyrolab ADA assays will be presented

John Chappell, Application & Service Director EMEA and Asia Pacific, Gyros Technologies